Boehringer Ingelheim has signed a deal to use Owkin's artificial intelligence model for discovering oncology and immunology drugs, joining AstraZeneca and Sanofi as major pharma clients of the AI platform.
The agreement marks Boehringer Ingelheim's entry into a growing trend of pharmaceutical companies leveraging machine learning for drug development. Owkin's AI model assists in identifying and validating new drug candidates across multiple therapeutic areas.
Boehringer Ingelheim joins AstraZeneca and Sanofi as prominent pharmaceutical partners utilizing Owkin's technology. The platform analyzes complex biological data to accelerate the discovery process, potentially reducing development timelines and costs.
Owkin, founded in 2016, combines federated learning with medical data to train AI models for drug discovery. The company has raised significant funding to expand its partnerships with major pharmaceutical companies seeking to integrate AI into their research pipelines.
The deal underscores the pharmaceutical industry's shift toward AI-assisted drug development as companies compete to bring new treatments to market more efficiently. Oncology and immunology remain high-priority therapeutic areas due to continued demand for novel treatment options.
A federal judge ruled Wednesday that Google does not have to divest its ad exchange. Instead, the company must integrate its ad tech tools with competing platforms.
A freedom of information request reveals the UK government lacks basic data on what its largest datacentres are being used for, raising concerns about the environmental footprint of AI expansion.
Communities worldwide are resisting plans for massive new datacentres, citing threats to energy supplies and climate goals. The pushback spans from Scotland to India as governments race to build AI infrastructure.
Shanghai Enflame Technology's initial public offering attracted 4,073 times oversubscription from retail investors. The Tencent-backed AI chipmaker becomes the latest of China's leading semiconductor designers to enter the public market.